TY - JOUR
T1 - Nirsevimab Administration During the Birth Hospitalization
AU - Daneshvari, Shayda
AU - Lee, Philip
AU - Nemerofsky, Sheri L.
N1 - Publisher Copyright:
Copyright © 2024 by the American Academy of Pediatrics.
PY - 2024/12
Y1 - 2024/12
N2 - Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization, occurring most often when the virus invades the lower respiratory tract. On July 17, 2023, the US Food and Drug Administration approved nirsevimab, a monoclonal antibody developed to protect infants against RSV infection. An early report showed the effectiveness of nirsevimab was 90% against RSV-associated hospitalization in infants during the first season.1 Nirsevimab became available for administration in the [location Bronx] mid-November 2023. The RSV season in New York is from November 1 through March 31.2 Two months before the approval of nirsevimab, the bivalent RSVpreF vaccine became available to birthing parents. This vaccine is recommended to be administered between 32 and 36 weeks’ gestation to protect infants against RSV. If the birthing parents received RSVpreF more than 14 days before delivery, the infant is not eligible for nirsevimab. The distribution of nirsevimab is supported by the Vaccine for Children program (VFC), a Title XIX Medicaid-funded program to provide free vaccines to children younger than age 18 years. This is the first monoclonal antibody included in their program. Eligibility for VFC includes children who are uninsured, underinsured, Medicaid-eligible, Medicaid-enrolled, American Indian, or Alaska Native.3 The hospital system in which this study was conducted secured an ample supply of Medicaid-funded nirsevimab for the 2023–2024 RSV season. Nirsevimab is the newest birth hospitalization immunization approved since the hepatitis B vaccine in 1991. The American Academy of Pediatrics recommends that newborns receive nirsevimab just before their discharge from the hospital or within the first week of life and the hepatitis B vaccine within 24 hours of life.4 The primary objective of this study was to determine the birth hospital nirsevimab administration rate. The secondary objective was to compare this rate to that of the hepatitis B vaccine administration at the same institution.
AB - Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization, occurring most often when the virus invades the lower respiratory tract. On July 17, 2023, the US Food and Drug Administration approved nirsevimab, a monoclonal antibody developed to protect infants against RSV infection. An early report showed the effectiveness of nirsevimab was 90% against RSV-associated hospitalization in infants during the first season.1 Nirsevimab became available for administration in the [location Bronx] mid-November 2023. The RSV season in New York is from November 1 through March 31.2 Two months before the approval of nirsevimab, the bivalent RSVpreF vaccine became available to birthing parents. This vaccine is recommended to be administered between 32 and 36 weeks’ gestation to protect infants against RSV. If the birthing parents received RSVpreF more than 14 days before delivery, the infant is not eligible for nirsevimab. The distribution of nirsevimab is supported by the Vaccine for Children program (VFC), a Title XIX Medicaid-funded program to provide free vaccines to children younger than age 18 years. This is the first monoclonal antibody included in their program. Eligibility for VFC includes children who are uninsured, underinsured, Medicaid-eligible, Medicaid-enrolled, American Indian, or Alaska Native.3 The hospital system in which this study was conducted secured an ample supply of Medicaid-funded nirsevimab for the 2023–2024 RSV season. Nirsevimab is the newest birth hospitalization immunization approved since the hepatitis B vaccine in 1991. The American Academy of Pediatrics recommends that newborns receive nirsevimab just before their discharge from the hospital or within the first week of life and the hepatitis B vaccine within 24 hours of life.4 The primary objective of this study was to determine the birth hospital nirsevimab administration rate. The secondary objective was to compare this rate to that of the hepatitis B vaccine administration at the same institution.
UR - http://www.scopus.com/inward/record.url?scp=85210945411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85210945411&partnerID=8YFLogxK
U2 - 10.1542/hpeds.2024-007911
DO - 10.1542/hpeds.2024-007911
M3 - Article
C2 - 39539134
AN - SCOPUS:85210945411
SN - 2154-1663
VL - 14
SP - e513-e516
JO - Hospital Pediatrics
JF - Hospital Pediatrics
IS - 12
ER -